uniQure N.V. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value
uniQure N.V. (QURE) had Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value of $18.74 million as of 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Notes › Fair Value Disclosures
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue · last filed 2026-03-02
- 2025-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $18.74M.
- 2024-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $10.86M.
- 2023-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $43.01M.
- 2022-12-31: Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value $35.32M.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value |
|---|---|
| 2025-12-31 | $18.74M 10-K · filed 2026-03-02 |
| 2024-12-31 | $10.86M 10-K · filed 2026-03-02 |
| 2023-12-31 | $43.01M 10-K · filed 2026-03-02 |
| 2022-12-31 | $35.32M 10-K · filed 2026-03-02 |
| 2021-12-31 | $32.35M 10-K · filed 2025-02-27 |
| 2020-12-31 | $2.65M 10-K · filed 2024-02-28 |
| 2020-09-30 | $500.00K 10-Q · filed 2020-10-27 |
| 2020-06-30 | $800.00K 10-Q · filed 2020-07-30 |
| 2020-03-31 | $1.00M 10-Q · filed 2020-04-29 |
| 2019-12-31 | $3.08M 10-K · filed 2023-02-27 |
| 2019-09-30 | $1.40M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $3.30M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $2.60M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $1.38M 10-K · filed 2022-02-25 |
| 2018-09-30 | $1.90M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $2.20M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $1.00M 10-Q · filed 2018-04-30 |
| 2017-12-31 | $5.60M 10-K · filed 2021-03-01 |
| 2017-09-30 | $3.65M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $2.45M 10-Q · filed 2017-08-08 |
| 2017-03-31 | $2.02M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $1.90M 10-K · filed 2020-03-02 |
| 2016-09-30 | $1.60M 10-Q · filed 2017-11-01 |
| 2016-06-30 | $3.44M 10-Q · filed 2017-08-08 |
| 2016-03-31 | $3.66M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $3.76M 10-K · filed 2019-02-28 |
| 2014-12-31 | $2.02M 10-K · filed 2018-03-14 |
| 2013-12-31 | $299.00K 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |